8-K current report · filed Nov 10, 2026

CorMedix Inc. (CRMD) 8-K Current Report: November 10, 2026

Item 7.01Item EX-99.1Item EX-99.2CRMD overview

Short answer

CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Proposed acquisition of substantially all Heron assets, adding four FDA-approved commercial brands to CorMedix’s portfolio.

CorMedix Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Proposed acquisition of substantially all Heron assets, adding four FDA-approved commercial brands to CorMedix’s portfolio
  • Transaction expected to diversify revenue, generate synergies and be earnings accretive, subject to closing conditions
  • CorMedix plans to issue common stock to Heron in a private placement, creating potential shareholder dilution
  • Investor presentation and conference-call transcript provide management’s transaction rationale and outlook
  • Key risks include Heron stockholder approval, regulatory clearances, integration execution, reimbursement changes and transaction financing

Item EX-99.1 · Exhibit EX-99.1

  • Heron acquisition adds 4 commercial products and approximately $150 million in trailing 12-month net product revenue
  • Upfront consideration: $145 million cash plus approximately 14.6 million CorMedix shares, valued at approximately $77.6 million at $5.32
  • Annual operating cost synergies targeted at $45 million to $60 million by year-end 2027
  • Financing includes a $150 million senior secured Pharmakon term facility, with $75 million drawn at closing
  • Additional earn-outs total up to $55 million, tied to 2028 ZYNRELEF sales thresholds of $65 million and $95 million

Item EX-99.2 · Exhibit EX-99.2

  • Proposed asset acquisition adds four FDA-approved brands, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL
  • Upfront consideration: $145 million cash plus 14,583,333 CorMedix shares valued at $7.20 each
  • Acquired products generated approximately $150 million in Q3 2026 LTM revenue
  • Management projects $45-$60 million annual synergies and $465-$490 million pro forma 2026E revenue
  • Closing targeted for Q1 2027, subject to Heron stockholder and regulatory approvals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CorMedix Inc. 8-K filings

Get the next CRMD 8-K as it lands

Follow CRMD for push alerts, or ask the research agent what this filing means.